Price target
3.690.000.00%
The 7 analysts offering 1 year price forecasts for 25K have a max estimate of — and a min estimate of —.
Analyst rating
Based on 7 analysts giving stock ratings to 25K in the past 3 months.
EPS
0.00
Reported
Estimate
Reported
Estimate
Surprise
Revenue
0.00
Reported
Estimate
Reported
Estimate
Surprise
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
25K EPS for the last quarter is −0.18 CHF despite the estimation of −0.27 CHF. In the next quarter EPS is expected to reach −0.22 CHF. Track more of KARYOPHARM THERAPE financials and stay on top of what is up with the company.
In the next quarter KARYOPHARM THERAPE revenue is expected to reach 32.31 M CHF. Check out KARYOPHARM THERAPE revenue and earnings and make informed decisions.
According to analysts, 25K price target is 3.69 CHF with a max estimate of 5.93 CHF and a min estimate of 1.70 CHF. Check if this forecast comes true in a year, meanwhile watch KARYOPHARM THERAPE stock price chart and keep track of the current situation with 25K news and stock market news.
We've gathered opinions of 7 analysts rating 25K stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as buy. Note that it's not a trading advice — your own analysis is still required.